Charles River: Flagship Pioneering, Pfizer, Charles River and Valo Health Collaborate to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease

Flagship Pioneering, announced an agreement between Pioneering Medicines, Flagship's in-house drug discovery and development unit, and Pfizer, to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases. The collaboration will engage Charles River to utilize Logica®, a unique platform offering from Valo Health, a Flagship-founded company, to identify advanceable small molecule leads. Logica translates biological insights into optimized preclinical assets by leveraging Valo Health's AI-powered Opal Computational Platform and Charles River's leading drug discovery expertise. This agreement represents the sixth collaboration signed under the broader strategic partnership between Flagship Pioneering and Pfizer to create a new pipeline of innovative assets, following programs announced with Flagship companies ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics, and Ampersand Biomedicines. Flagship Pioneering, announced an agreement between Pioneering Medicines, Flagship's in-house drug discovery and development unit, and Pfizer, to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases. The collaboration will engage Charles River to utilize Logica®, a unique platform offering from Valo Health, a Flagship-founded company, to identify advanceable small molecule leads. Logica translates biological insights into optimized preclinical assets by leveraging Valo Health's AI-powered Opal Computational Platform and Charles River's leading drug discovery expertise. This agreement represents the sixth collaboration signed under the broader strategic partnership between Flagship Pioneering and Pfizer to create a new pipeline of innovative assets, following programs announced with Flagship companies ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics, and Ampersand Biomedicines.